Frontotemporal Lobar Degeneration
28
5
7
18
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 28 trials
100.0%
+13.5% vs benchmark
7%
2 trials in Phase 3/4
11%
2 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (28)
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Neurofilament Surveillance Project (NSP)
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers
The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
Dopaminergic Therapy for Frontotemporal Dementia Patients
ADDIA Proof-of-Performance Clinical Study
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Effects of Tolcapone on Frontotemporal Dementia
Care Ecosystem: Navigating Patients and Families Through Stages of Care
Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial
Mindfulness-Based Stress Reduction in Dementia Caregivers
Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration.
Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease
Patients With Alzheimer's Disease or Related Youth Disease
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)